New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Vaccine boosts response of engineered T cells, may help eradicate solid tumors

Vaccine boosts response of engineered T cells, may help eradicate solid tumors

by Massachusetts Institute of TechnologyCredit: CC0 Public DomainEngineering T cells to destroy cancer cells has shown success in treating some types of cancer, such as leukemia and lymphoma. How
Oncology January 30,2024
Vaccine boosts response of engineered T cells, may help eradicate solid tumors

Vaccine boosts response of engineered T cells, may help eradicate solid tumors

by Massachusetts Institute of TechnologyCredit: CC0 Public DomainEngineering T cells to destroy cancer cells has shown success in treating some types of cancer, such as leukemia and lymphoma. How
Oncology January 30,2024
Investigating the immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy

Investigating the immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy

by Impact Journals LLCMultiple mechanisms underly the pro-tumorigenic role of CD200. Credit: 2023 Shao and Owens.A new research perspective titled "The immunoregulatory protein CD200 as a potenti
Oncology January 30,2024
Investigating the immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy

Investigating the immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy

by Impact Journals LLCMultiple mechanisms underly the pro-tumorigenic role of CD200. Credit: 2023 Shao and Owens.A new research perspective titled "The immunoregulatory protein CD200 as a potenti
Oncology January 30,2024
Study brings insight to kidney cancer with gene mutation

Study brings insight to kidney cancer with gene mutation

by Anna Megdell,University of MichiganCredit: Pixabay/CC0 Public DomainA new study from clinicians and researchers at the University of Michigan Rogel Cancer Center, U-M Department of Pathology
Oncology January 30,2024
Study brings insight to kidney cancer with gene mutation

Study brings insight to kidney cancer with gene mutation

by Anna Megdell,University of MichiganCredit: Pixabay/CC0 Public DomainA new study from clinicians and researchers at the University of Michigan Rogel Cancer Center, U-M Department of Pathology
Oncology January 30,2024
Possible therapeutic approach to fight incurable blood cancer

Possible therapeutic approach to fight incurable blood cancer

by Technical University MunichGraphical abstract. Credit:The EMBO Journal(2022). DOI: 10.15252/embj.2022110871Multiple myeloma (MM) is the second most common type of blood cancer. It
Oncology January 30,2024
Possible therapeutic approach to fight incurable blood cancer

Possible therapeutic approach to fight incurable blood cancer

by Technical University MunichGraphical abstract. Credit:The EMBO Journal(2022). DOI: 10.15252/embj.2022110871Multiple myeloma (MM) is the second most common type of blood cancer. It
Oncology January 30,2024
A new drug prevents epithelial-mesenchymal transition, metastasis and resistance to anti-cancer therapy

A new drug prevents epithelial-mesenchymal transition, metastasis and resistance to anti-cancer therapy

by Université libre de BruxellesTargeting netrin-1 reduces metastasis and sensitizes tumor cells to chemotherapy in skin SCC.a, Dot plot showing the number of spontaneous lung metastases in
Oncology January 30,2024
A new drug prevents epithelial-mesenchymal transition, metastasis and resistance to anti-cancer therapy

A new drug prevents epithelial-mesenchymal transition, metastasis and resistance to anti-cancer therapy

by Université libre de BruxellesTargeting netrin-1 reduces metastasis and sensitizes tumor cells to chemotherapy in skin SCC.a, Dot plot showing the number of spontaneous lung metastases in
Oncology January 30,2024
Researchers show how a tumor cell's location and environment affect its identity

Researchers show how a tumor cell's location and environment affect its identity

by National Institutes of HealthDifferences in cell layers' fluorescent-dye uptake in a model of high-grade serous ovarian cancer. Credit: David B. Morse.Using 3D models of ovarian cancer tum
Oncology January 30,2024
Researchers show how a tumor cell's location and environment affect its identity

Researchers show how a tumor cell's location and environment affect its identity

by National Institutes of HealthDifferences in cell layers' fluorescent-dye uptake in a model of high-grade serous ovarian cancer. Credit: David B. Morse.Using 3D models of ovarian cancer tum
Oncology January 30,2024
Researchers analyze cancer discrepancies among young Black men in the South

Researchers analyze cancer discrepancies among young Black men in the South

by Vinod Hopson,University of Texas Health Science Center at HoustonRegional Kaposi sarcoma incidence rate trends in non-Hispanic White men aged 20-34. Abbreviation: AAPC, average annual percent
Oncology January 30,2024
Researchers analyze cancer discrepancies among young Black men in the South

Researchers analyze cancer discrepancies among young Black men in the South

by Vinod Hopson,University of Texas Health Science Center at HoustonRegional Kaposi sarcoma incidence rate trends in non-Hispanic White men aged 20-34. Abbreviation: AAPC, average annual percent
Oncology January 30,2024
Support for home cancer testing

Support for home cancer testing

by Flinders UniversityCredit: Pixabay/CC0 Public DomainScreening for bowel cancer using at-home fecal immunochemical tests could help to reduce the frequency of colonoscopies for some at above-av
Oncology January 30,2024
Support for home cancer testing

Support for home cancer testing

by Flinders UniversityCredit: Pixabay/CC0 Public DomainScreening for bowel cancer using at-home fecal immunochemical tests could help to reduce the frequency of colonoscopies for some at above-av
Oncology January 30,2024
Researchers map activity of inherited gene variants linked to prostate cancer

Researchers map activity of inherited gene variants linked to prostate cancer

by UT Southwestern Medical CenterCredit: Pixabay/CC0 Public DomainUT Southwestern researchers have identified the molecular function of 87 inherited genetic variants that affect the risk of prost
Oncology January 30,2024
Researchers map activity of inherited gene variants linked to prostate cancer

Researchers map activity of inherited gene variants linked to prostate cancer

by UT Southwestern Medical CenterCredit: Pixabay/CC0 Public DomainUT Southwestern researchers have identified the molecular function of 87 inherited genetic variants that affect the risk of prost
Oncology January 30,2024
Researchers uncover potential biomarkers of positive response to immunotherapy

Researchers uncover potential biomarkers of positive response to immunotherapy

by Denise Heady,University of California, Los AngelesResponse to ICI or MAPKi therapy is associated with increased T cell infiltration and enhanced interferon gamma (IFNγ) pathway activity in th
Oncology January 30,2024
Researchers uncover potential biomarkers of positive response to immunotherapy

Researchers uncover potential biomarkers of positive response to immunotherapy

by Denise Heady,University of California, Los AngelesResponse to ICI or MAPKi therapy is associated with increased T cell infiltration and enhanced interferon gamma (IFNγ) pathway activity in th
Oncology January 30,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com